Medications for Obesity

医学 利拉鲁肽 减肥 奥利斯特 不利影响 肥胖 芬特明 安非他酮 恶心 食欲 2型糖尿病 内科学 内分泌学 糖尿病 戒烟 病理
作者
Kimberly A. Gudzune,Robert F. Kushner
出处
期刊:JAMA [American Medical Association]
卷期号:332 (7): 571-571 被引量:193
标识
DOI:10.1001/jama.2024.10816
摘要

Importance: Obesity affects approximately 19% of women and 14% of men worldwide and is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite and significantly improve outcomes, such as type 2 diabetes, hypertension, and dyslipidemia. Observations: AOMs should be administered in combination with lifestyle interventions and can be classified according to their mechanisms of action. Orlistat modifies digestive tract absorption and causes gastrointestinal adverse effects, such as oily fecal spotting and urgency, in more than 25% of patients. Centrally acting drugs, such as phentermine-topiramate and naltrexone-bupropion, regulate appetite in the brain and are associated with constipation in approximately 20% of patients, although the incidence of other adverse effects (eg, paresthesia, nausea) varies by medication. Nutrient-stimulated hormone-based medications, such as liraglutide, semaglutide, and tirzepatide, mimic the actions of enteropancreatic hormones that modify central appetite regulation and provide multiple cardiometabolic weight-loss benefits. Adverse effects of these drugs include nausea (28%-44%), diarrhea (21%-30%), and constipation (11%-24%). The relative potency of adult obesity medications has been studied in meta-analyses. Compared with placebo, orlistat was associated with 3.1% greater weight loss (52 randomized clinical trials [RCTs]; 16 964 participants), phentermine-topiramate was associated with 8.0% greater weight loss (5 RCTs; 3407 participants), naltrexone-bupropion was associated with 4.1% greater weight loss (6 RCTs; 9949 participants), liraglutide was associated with 4.7% greater weight loss (18 RCTs; 6321 participants), semaglutide was associated with 11.4% greater weight loss (5 RCTs; 4421 participants), and tirzepatide 15 mg was associated with 12.4% greater weight loss (6 RCTs; 1972 participants). Conclusion and Relevance: Obesity is associated with increased morbidity. Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
故风完成签到,获得积分10
1秒前
2秒前
3秒前
CipherSage应助不系舟采纳,获得10
3秒前
NiaoJiang完成签到,获得积分10
4秒前
4秒前
冷静火龙果完成签到,获得积分10
5秒前
uuu发布了新的文献求助10
5秒前
Lucas应助nadeem采纳,获得10
6秒前
7秒前
张熙良发布了新的文献求助10
8秒前
禹宛白发布了新的文献求助10
8秒前
8秒前
9秒前
哭泣尔安完成签到 ,获得积分10
9秒前
无极微光应助科2研7通采纳,获得20
9秒前
TTYYI完成签到 ,获得积分10
12秒前
12秒前
Pha66完成签到,获得积分10
12秒前
12秒前
爱咋咋地完成签到,获得积分10
13秒前
星星发布了新的文献求助10
13秒前
好心秦发布了新的文献求助10
15秒前
小呵点完成签到 ,获得积分0
16秒前
科研通AI2S应助pete采纳,获得10
16秒前
17秒前
17秒前
幸运Q发布了新的文献求助10
17秒前
18秒前
传奇3应助禹宛白采纳,获得10
18秒前
Cuibuqu完成签到 ,获得积分10
19秒前
宇宙中的先行者完成签到,获得积分10
20秒前
崔志玥发布了新的文献求助10
23秒前
nadeem发布了新的文献求助10
23秒前
古惑仔完成签到 ,获得积分10
24秒前
25秒前
大角牛完成签到,获得积分10
25秒前
蒋念寒发布了新的文献求助10
26秒前
27秒前
高分求助中
Psychopathic Traits and Quality of Prison Life 1000
Chemistry and Physics of Carbon Volume 18 800
The formation of Australian attitudes towards China, 1918-1941 660
Signals, Systems, and Signal Processing 610
天津市智库成果选编 600
Forced degradation and stability indicating LC method for Letrozole: A stress testing guide 500
全相对论原子结构与含时波包动力学的理论研究--清华大学 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6451889
求助须知:如何正确求助?哪些是违规求助? 8263655
关于积分的说明 17609083
捐赠科研通 5516561
什么是DOI,文献DOI怎么找? 2903818
邀请新用户注册赠送积分活动 1880790
关于科研通互助平台的介绍 1722669